RedHill Biopharma (NASDAQ:RDHL) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of RedHill Biopharma (NASDAQ:RDHL) in a report published on Saturday. The firm issued a hold rating on the biotechnology company’s stock.

RedHill Biopharma Stock Performance

RDHL opened at $0.45 on Friday. The business has a fifty day simple moving average of $0.49 and a 200 day simple moving average of $0.75. RedHill Biopharma has a 1 year low of $0.26 and a 1 year high of $3.28.

Institutional Trading of RedHill Biopharma

A hedge fund recently bought a new stake in RedHill Biopharma stock. Armistice Capital LLC bought a new stake in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 722,894 shares of the biotechnology company’s stock, valued at approximately $369,000. Armistice Capital LLC owned 6.53% of RedHill Biopharma as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 7.20% of the company’s stock.

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.